Why Is Kairos Pharma Stock Surging On Tuesday?
1. KAPA stock surged 57.64% on high volume of 221 million shares. 2. Phase 2 trial of ENV-105 shows positive safety results in prostate cancer patients. 3. No severe toxicities were reported, indicating favorable treatment tolerability. 4. Kairos plans to engage regulators for a potential Phase 3 study. 5. Interim efficacy data from the trial expected by September 2025.